Boston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25^th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on Jan.13-15, 2022. More than 20 abstracts have been accepted, including three late-breaking presentations.

The late-breaking presentation on the COMBO study, a randomized control trial, will highlight two-year outcomes demonstrating the durable effectiveness of WaveWriter^TM Spinal Cord Stimulator (SCS) System capable of delivering combination therapy - the ability to layer multiple waveforms and modalities simultaneously. Combination therapy is designed to offer more opportunities to customize SCS therapy and optimize outcomes.

In addition, Boston Scientific and IBM Research will provide an update from their exclusive collaboration, which includes the ongoing NAVITAS and ENVISION studies evaluating how patient-reported outcomes and objective biomarker information can provide insights around patient pain states. This novel approach leverages artificial intelligence to better understand and assess the pain state of an individual that includes activity, alertness, medication, mobility, mood, pain and sleep.

"The data we'll share this year at NANS is a testament to the breadth and depth of the randomized controlled and real-world evidence of our portfolio and therapies," said Nilesh Kumar Patel, M.D., MBA, vice president of medical affairs, Neuromodulation, Boston Scientific. "Our long-term investments in science and innovation, continues to deliver more meaningful solutions and customized options for physicians and their patients living with chronic pain."

Patel added, "The condition of chronic pain is complex, and because of neuroplasticity, it changes over time. As a result, you need an agile platform with multiple options that adapts with the changing needs of the patient. No one patient living with chronic pain is the same so we're continuously working to advance and transform personalized therapies for the future to help patients live healthier lives."

Featured Abstracts

Oral Presentations:

• COMBO Randomized Control Trial: Two-Year Outcomes of an SCS System Capable of Simultaneous Delivery of Multiple Modalities to be presented by Mark Wallace, M.D., on Saturday, Jan. 15 from 4:25-4:35 p.m. ET
• Patient States: Artificial Intelligence-Driven Metric Providing Comprehensive Yet Straightforward Understanding of Chronic Pain Patients to be presented by Magdalena Anitescu, M.D., Ph.D., on Friday, Jan. 14 from 11:35-11:45 a.m. ET
• Prospective, Multi-center Evaluation of Novel Fast-Acting Sub-Perception-Based SCS for Chronic Pain: FAST Study to be presented by Magdalena Anitescu, M.D., Ph.D., on Friday, Jan. 15 from 4:15-4:25 p.m. ET

Paper Posters:

• RAPID: An International, Prospective, Multicenter Study of Radiofrequency Ablation Outcomes in Chronic Pain Patients, Atallah et al.
• Comprehensive Digital Tools to Improve Access to Care and Treatment Efficiency for Spinal Cord Stimulation, Vucetic et al.
• Modeling and Measurement of the Effect of Low-Amplitude SCS on Dorsal Column Axons and Wide Dynamic Range Neurons, Titus et al.
• The Biomechanics of Interspinous Spacers, Whang et al.

Publication will be made available after the release of the data presentations.